Cargando…
Therapeutic Options for Visceral Leishmaniasis
Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geogra...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837193/ https://www.ncbi.nlm.nih.gov/pubmed/24170666 http://dx.doi.org/10.1007/s40265-013-0133-0 |
_version_ | 1782292410413350912 |
---|---|
author | Monge-Maillo, Begoña López-Vélez, Rogelio |
author_facet | Monge-Maillo, Begoña López-Vélez, Rogelio |
author_sort | Monge-Maillo, Begoña |
collection | PubMed |
description | Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection. |
format | Online Article Text |
id | pubmed-3837193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-38371932013-11-29 Therapeutic Options for Visceral Leishmaniasis Monge-Maillo, Begoña López-Vélez, Rogelio Drugs Review Article Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection. Springer International Publishing 2013-10-30 2013 /pmc/articles/PMC3837193/ /pubmed/24170666 http://dx.doi.org/10.1007/s40265-013-0133-0 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.5/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Article Monge-Maillo, Begoña López-Vélez, Rogelio Therapeutic Options for Visceral Leishmaniasis |
title | Therapeutic Options for Visceral Leishmaniasis |
title_full | Therapeutic Options for Visceral Leishmaniasis |
title_fullStr | Therapeutic Options for Visceral Leishmaniasis |
title_full_unstemmed | Therapeutic Options for Visceral Leishmaniasis |
title_short | Therapeutic Options for Visceral Leishmaniasis |
title_sort | therapeutic options for visceral leishmaniasis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837193/ https://www.ncbi.nlm.nih.gov/pubmed/24170666 http://dx.doi.org/10.1007/s40265-013-0133-0 |
work_keys_str_mv | AT mongemaillobegona therapeuticoptionsforvisceralleishmaniasis AT lopezvelezrogelio therapeuticoptionsforvisceralleishmaniasis |